Differently expressed microRNA in response to the first Ig replacement therapy in common variable immunodeficiency patients

Abstract

Common variable immunodeficiency (CVID) is a complex primary immunodeficiency disorder characterized by a high clinical and genetic heterogeneity. The molecular underlying causes of CVID are not still now clear and the delays in diagnosis and treatment worsen the prognosis of the patients. MicroRNAs are non-coding, endogenous small RNAs often deregulated in human diseases, such as autoimmune and other immune-based disorders. In the present study, we aimed to evaluate miRNAs associated with the CVID and, in particular, with the response to the first Ig replacement therapy. To this aim, we compared miRNA profile obtained by serum samples of treatment-naïve CVID patients before and 24 h after the first Ig replacement therapy. For the first time, using a microarray assay followed by an integrated bioinformatics/biostatistics analysis, we identified five microRNAs (hsa-miR-6742, hsa-miR-1825, hsa-miR-4769-3p, hsa-miR-1228-3p, hsa-miR-1972) differently modulated in CVID patients by Ig infusion. All of them were down-regulated, excepted miR-6742 which was up-regulated. The latter may be of particular interest, since its functions are related to pathways involving Class I MHC mediated antigen processing and adaptive as well as innate Immune System. In conclusion, this study shows for the first time the modulation of miRNAs involved in CVID patients after the first Ig replacement therapy. Further studies are needed to assess whether such miRNAs could represent novel potential biomarkers in management and therapy of CVID patients.

Identifying circRNA-associated-ceRNA networks in juvenile spondyloarthropathies patients.

“…Regarding miRNAs, the seven miRNAs identi ed in our study have been widely reported in various diseases [28][29][30][31][32]. For example, hsa-miR-1825 was found to be down-regulated in patients with common variable immunode ciency (CVID) who received Ig infusion [33],…”

miR-31-5p as a Potential Circulating Biomarker and Tracer of Clinical Improvement for Chronic Inflammatory Demyelinating Polyneuropathy

“…Additionally, IVIg is thought to interfere 7 Oxidative Medicine and Cellular Longevity with the passage of autoimmune cells across the bloodnerve barrier and to reduce antibody production by B cells, interfere with B cell proliferation through cell surface receptors, block the activity of certain B cell subtypes, interrupt several steps in the complement activation cascade, and affect activity mediated by the Fc receptor [31,34]. The correlations between IVIg treatment effectiveness and miRNA level were described in many studies in different clinical situations [35][36][37][38]. IVIg replacement therapy in different immunodeficiency patients is thought to be able to modulate miRNA level.…”

COVID-19 Vaccination in Pregnancy: Pilot Study for Maternal and Neonatal MicroRNA Profiles

“…In previous studies, miR-1972 has been identified to regulate various targets, including EDN1, CD274, and PDCD1LG2 [ 33 ]. These targets play pivotal roles in processes such as respiratory burst and T-cell activation, highlighting miR-1972’s association with T and B cell signaling as well as TNFR1 signaling pathways [ 34 ]. Notably, in the context of chronic myeloid leukemia, overexpression of miR-1972 has been linked to cell cycle arrest at the G2-M phase [ 35 ].…”